<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23019" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Human Chorionic Gonadotropin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Betz</surname>
            <given-names>Danielle</given-names>
          </name>
          <aff>Temple University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fane</surname>
            <given-names>Kathleen</given-names>
          </name>
          <aff>Temple University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Danielle Betz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kathleen Fane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23019.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Human chorionic gonadotropin (hCG) is a chemical created by trophoblast tissue, tissue typically found&#x000a0;in early embryos and which will eventually be part of the placenta. Measuring hCG levels can be helpful in identifying a normal pregnancy, pathologic pregnancy,&#x000a0;and can also be useful following an aborted pregnancy. There is also a benefit in measuring hCG in a variety of cancers including choriocarcinoma and extra-uterine malignancies.</p>
      </sec>
      <sec id="article-23019.s2" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>Human chorionic gonadotropin is a hormone produced primarily by syncytiotrophoblastic cells of the placenta during pregnancy. The hormone stimulates the corpus luteum to produce progesterone to maintain the pregnancy. Smaller amounts of hCG are also produced in the pituitary gland, the liver, and the colon.<xref ref-type="bibr" rid="article-23019.r1">[1]</xref>&#x000a0;As previously mentioned, certain malignancies can also produce either hCG or hCG-related hormone. Trophoblastic cancers (hydatidiform mole, choriocarcinoma, and germ cell tumors)&#x000a0;are associated with high serum levels of hCG-related molecules.</p>
        <p>The hormone itself is a glycoprotein composed of two subunits, the alpha and beta subunits.<xref ref-type="bibr" rid="article-23019.r1">[1]</xref>&#x000a0;There are multiple forms found in the serum and urine during pregnancy including the intact hormone and each of the free subunits. HCG is primarily catabolized by the liver,&#x000a0;although about 20% is excreted in the urine. The beta subunit is degraded in the kidney to make a core fragment which is&#x000a0;measured by urine hCG tests.</p>
      </sec>
      <sec id="article-23019.s3" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>
<bold>Urine Testing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Urine should not be collected after the patient has been drinking a large amount of fluid, as a dilute specimen may result in a falsely negative test.<xref ref-type="bibr" rid="article-23019.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Blood in the urine may cause a false positive test result.</p>
          </list-item>
        </list>
        <p>
<bold>Serum Testing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Peripheral blood can be obtained for a serum hCG test.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23019.s4" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>Serum tests for hCG are immunometric assays. This means that&#x000a0;they use 2two antibodies that bind to the hCG molecule, a fixed antibody and a radiolabeled antibody which adhere to different sites on the molecule, sandwiching and immobilize the molecule to make it detectable.<xref ref-type="bibr" rid="article-23019.r3">[3]</xref>&#x000a0;Assays involve washing away the excess serum components and measuring the amount of remaining labeled hCG to give a quantitative result. There are more than 100 different assays commercially available which results in significant variability in reported values.</p>
        <p>Urine assays are similar, although many detect total hCG levels greater than 20 mIU/mL.<xref ref-type="bibr" rid="article-23019.r4">[4]</xref>&#x000a0;Many over-the-counter urine pregnancy tests do not detect hyperglycosylated hCG, which accounts for most of the hCG in early pregnancy, resulting in a wide range of sensitivities of these tests.</p>
        <p>Serum testing is much more sensitive and specific than urine testing. Urine testing, however, is more convenient, affordable, comfortable for patients, has a fast turnaround (5 to 10 minutes), and does not require a medical prescription.</p>
      </sec>
      <sec id="article-23019.s5" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>
<bold>Urine Testing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Urine is placed in or on a designated receptacle (most commercially available and medical point of care tests)</p>
          </list-item>
          <list-item>
            <p>An indicator (typically a colored line or symbol), along with a control, will appear if the test is positive</p>
          </list-item>
          <list-item>
            <p>An isolated control line/symbol will be evident if the test is negative</p>
          </list-item>
        </list>
        <p>
<bold>Serum Testing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum&#x000a0;hCG&#x000a0;testing&#x000a0;is performed in a laboratory equipped with the proper machinery and uses a peripheral blood sample</p>
          </list-item>
          <list-item>
            <p>If a hook effect/gestational&#x000a0;trophoblastic disease is suspected, the lab should perform a dilution&#x000a0;prior to&#x000a0;testing</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23019.s6" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>There are multiple reasons why&#x000a0;an hCG test (serum or urine) may have a false report. While uncommon, false positive hCG tests can result in unnecessary medical care&#x000a0;and/or irreversible surgical procedures. False negatives may be equally concerning and result in a&#x000a0;delay in care or diagnostic evaluation. Potential causes of false results are listed and briefly discussed.</p>
        <p>
<bold>Serum False Positives&#x000a0;(1/1000 to 1/10,000)</bold>
<xref ref-type="bibr" rid="article-23019.r5">[5]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ectopic production of hCG (hydatidiform mole, choriocarcinoma, and germ cell tumors,<xref ref-type="bibr" rid="article-23019.r6">[6]</xref>, in addition to multiple myeloma, stomach, liver, lung, bladder, pancreatic, breast, colon, cervical, and endometrial cancers)<xref ref-type="bibr" rid="article-23019.r7">[7]</xref><xref ref-type="bibr" rid="article-23019.r8">[8]</xref><xref ref-type="bibr" rid="article-23019.r9">[9]</xref><xref ref-type="bibr" rid="article-23019.r10">[10]</xref><xref ref-type="bibr" rid="article-23019.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Heterophile antibodies (autoantibodies and antibodies formed after exposure to animal products that interact with the assay antibodies)<xref ref-type="bibr" rid="article-23019.r12">[12]</xref><xref ref-type="bibr" rid="article-23019.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Rheumatoid factors (can bind the antibodies in the assay as well)</p>
          </list-item>
          <list-item>
            <p>IgA deficiency<xref ref-type="bibr" rid="article-23019.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic renal failure or ESRD on hemodialysis (rare)<xref ref-type="bibr" rid="article-23019.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Red blood cell or plasma transfusion of blood with hCG in it have been reported</p>
          </list-item>
          <list-item>
            <p>Exogenous hCG preparations for weight loss, assisted reproduction, doping<xref ref-type="bibr" rid="article-23019.r16">[16]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Serum False Negatives</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Early measurement after conception&#x000a0;</p>
          </list-item>
          <list-item>
            <p>"Hook effect" can occur when hCG levels are about 500,000 mIU/mL.<xref ref-type="bibr" rid="article-23019.r17">[17]</xref>&#x000a0;This is because there are so many hCG molecules that&#x000a0;they saturate both the tracer and the antibodies separately, which doesn't allow for the sandwiching of the tracer-hCG-antibody required for the measurement. This means that&#x000a0;all of the complexes are washed away, giving a false-negative result. If&#x000a0;gestational&#x000a0;trophoblastic disease is suspected, the lab should perform a dilution prior to testing.</p>
          </list-item>
        </list>
        <p>
<bold>Urine False Positives</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Blood or protein in the urine</p>
          </list-item>
          <list-item>
            <p>Human error in result interpretation</p>
          </list-item>
          <list-item>
            <p>Ectopic production of hCG</p>
          </list-item>
          <list-item>
            <p>Exogenous hCG</p>
          </list-item>
          <list-item>
            <p>Drugs (aspirin, carbamazepine, methadone, high urinary pH and seminal fluid)<xref ref-type="bibr" rid="article-23019.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Urine False Negatives</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Early measurement after conception</p>
          </list-item>
          <list-item>
            <p>Dilute urine specimen<xref ref-type="bibr" rid="article-23019.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>"Hook effect" as discussed above</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23019.s7" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>HCG&#x000a0;levels&#x000a0;are&#x000a0;reported in milli-international units of hCG hormone per milliliter of blood, or&#x000a0;mIU/mL. International&#x000a0;unit per liter (IU/L) may also be&#x000a0;used.</p>
        <p>Urine hCG testing is qualitative, reporting a positive or negative result. The assays detect hCG levels typically starting at 20 to 50 (reportedly as low as 6.3 to 12.5)<xref ref-type="bibr" rid="article-23019.r19">[19]</xref>&#x000a0;mIU/mL, corresponding to levels at approximately 4 weeks post-conception.&#x000a0;</p>
        <p>Serum assays can measure beta-hCG as low as 1 to 2 mIU/mL.</p>
      </sec>
      <sec id="article-23019.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Pregnancy</bold>
</p>
        <p>HCG is an important hormone in pregnancy, and its clinical utility is primarily centered around its detection in early pregnancy, along with serial measurement during pregnancy and pregnancy-related complications.</p>
        <p>Levels of hCG can vary widely&#x000a0;between women with normal pregnancies. Typically, serum&#x000a0;and urine concentrations of hCG&#x000a0;rise exponentially in the first trimester of pregnancy, doubling about every 24 hours during the first 8 weeks. The peak is usually around 10 weeks of gestation and then levels decrease until about the 16th week of gestation where they remain fairly constant until term.<xref ref-type="bibr" rid="article-23019.r3">[3]</xref></p>
        <p>Patients who have hCG levels that plateau prior to 8 weeks or that fail to double commonly have a nonviable pregnancy, whether intra-uterine or extra-uterine. Extra-uterine (ectopic) pregnancies usually have a rate-of-rise that is&#x000a0;low without the typical doubling. However, given the large range of normal hCG levels and inconsistent rates-of-rise of this hormone, checking serum levels is typically paired with ultrasound evaluation to improve sensitivity and specificity.<xref ref-type="bibr" rid="article-23019.r20">[20]</xref></p>
        <p>Return of hCG to zero following delivery or termination of pregnancy ranges from 7 to 60 days.<xref ref-type="bibr" rid="article-23019.r21">[21]</xref>&#x000a0;Trending the fall of hCG levels can be important in termination of molar pregnancies and also following the termination of normal or ectopic pregnancies to be assured that the therapy has been successful.</p>
        <p>It notable that there are many different combinations of antibodies used in commercial&#x000a0;assays. This results in heterogeneous results with as much as a 50-fold difference in immunoassay results.<xref ref-type="bibr" rid="article-23019.r3">[3]</xref>&#x000a0;This is clinically relevant, particularly when comparing results from different laboratories in different facilities/hospitals when examining low&#x000a0;values following pregnancy termination or trophoblastic disease.</p>
        <p>
<bold>Gestational Trophoblastic Disease</bold>
</p>
        <p>Detection of hCG is also useful in&#x000a0;the evaluation of trophoblastic disease, including complete and partial&#x000a0;hydatidiform mole,&#x000a0;postmolar&#x000a0;tumor, gestational choriocarcinoma, testicular choriocarcinoma, and placental site trophoblastic disease. All of these entities produce hCG, varying levels of which are reported on commercial assays.&#x000a0;A total hCG level of greater than 100,000 mIU/mL in early pregnancy, for example, is highly suggestive of a complete hydatidiform mole,<xref ref-type="bibr" rid="article-23019.r22">[22]</xref>&#x000a0;although many normal pregnancies may reach this level at their peak around weeks 8 to 11 of gestation.&#x000a0;Precise hCG&#x000a0;measurements&#x000a0;are&#x000a0;important to assess the tumor mass, the successful treatment of malignancy, and to test for recurrence or persistence of disease.<xref ref-type="bibr" rid="article-23019.r6">[6]</xref></p>
        <p>
<bold>Non-Pregnant Patients</bold>
</p>
        <p>HCG in the serum increases with age in nonpregnant women. A cut off of 14 mIU/mL&#x000a0;has been suggested for use in&#x000a0;interpreting results in women over the age of 55. In all nonpregnant patients, testicular cancer, ovarian cancer, bladder cancer, or other malignancy should be evaluated&#x000a0;as a source of persistently positive&#x000a0;hCG testing.</p>
      </sec>
      <sec id="article-23019.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Knowing the utility and variability of different hCG assays is clinically relevant to a wide range of medical providers. False positive and false negative testing has a large impact on patient care. All providers in a patient care team should be aware of common limitations in testing, for example, urine assay false positives with hematuria, false negatives with dilute urine, along with more obscure but&#x000a0;still very relevant causes of inaccurate testing.&#x000a0;Interpreting results that may be false should&#x000a0;be undergone&#x000a0;with care to help prevent unnecessary testing and treatment.<xref ref-type="bibr" rid="article-23019.r23">[23]</xref>&#x000a0;(Level V) Collaboration, shared decision making, and communication&#x000a0;are&#x000a0;critical&#x000a0;elements in&#x000a0;good patient care.</p>
      </sec>
      <sec id="article-23019.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23019&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23019">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23019/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23019">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23019.s11">
        <title>References</title>
        <ref id="article-23019.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montagnana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trenti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aloe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cervellin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lippi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Human chorionic gonadotropin in pregnancy diagnostics.</article-title>
            <source>Clin Chim Acta</source>
            <year>2011</year>
            <month>Aug</month>
            <day>17</day>
            <volume>412</volume>
            <issue>17-18</issue>
            <fpage>1515</fpage>
            <page-range>1515-20</page-range>
            <pub-id pub-id-type="pmid">21635878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beebeejaun</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The effect of physiological urine dilution on pregnancy test results in complicated early pregnancies.</article-title>
            <source>Br J Obstet Gynaecol</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>106</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-8</page-range>
            <pub-id pub-id-type="pmid">10426268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cole</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites.</article-title>
            <source>Clin Chem</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>2233</fpage>
            <page-range>2233-43</page-range>
            <pub-id pub-id-type="pmid">9439438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greene</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Kamer</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Grenache</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Hoke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lorey</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Limitations in qualitative point of care hCG tests for detecting early pregnancy.</article-title>
            <source>Clin Chim Acta</source>
            <year>2013</year>
            <month>Jan</month>
            <day>16</day>
            <volume>415</volume>
            <fpage>317</fpage>
            <page-range>317-21</page-range>
            <pub-id pub-id-type="pmid">23159297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braunstein</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>False-positive serum human chorionic gonadotropin results: causes, characteristics, and recognition.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>187</volume>
            <issue>1</issue>
            <fpage>217</fpage>
            <page-range>217-24</page-range>
            <pub-id pub-id-type="pmid">12114913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cole</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Shahabi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Newlands</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Behrman</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Verrill</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Utility of commonly used commercial human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic diseases.</article-title>
            <source>Clin Chem</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>308</fpage>
            <page-range>308-15</page-range>
            <pub-id pub-id-type="pmid">11159780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcillac</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Troalen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bidart</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ghillani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ribrag</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Escudier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Malassagne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Droz</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lhomm&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rougier</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms.</article-title>
            <source>Cancer Res</source>
            <year>1992</year>
            <month>Jul</month>
            <day>15</day>
            <volume>52</volume>
            <issue>14</issue>
            <fpage>3901</fpage>
            <page-range>3901-7</page-range>
            <pub-id pub-id-type="pmid">1377600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alfthan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haglund</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stenman</surname>
                <given-names>UH</given-names>
              </name>
            </person-group>
            <article-title>Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease.</article-title>
            <source>Cancer Res</source>
            <year>1992</year>
            <month>Sep</month>
            <day>01</day>
            <volume>52</volume>
            <issue>17</issue>
            <fpage>4628</fpage>
            <page-range>4628-33</page-range>
            <pub-id pub-id-type="pmid">1324787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheaff</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Badenoch</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Baithun</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>beta hCG as a prognostic marker in adenocarcinoma of the prostate.</article-title>
            <source>J Clin Pathol</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>329</fpage>
            <page-range>329-32</page-range>
            <pub-id pub-id-type="pmid">8655711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lundin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nordling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carpelan-Holmstrom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Louhimo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alfthan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stenman</surname>
                <given-names>UH</given-names>
              </name>
              <name>
                <surname>Haglund</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A comparison of serum and tissue hCG beta as prognostic markers in colorectal cancer.</article-title>
            <source>Anticancer Res</source>
            <year>2000</year>
            <season>Nov-Dec</season>
            <volume>20</volume>
            <issue>6D</issue>
            <fpage>4949</fpage>
            <page-range>4949-51</page-range>
            <pub-id pub-id-type="pmid">11326644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reisenbichler</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Krontiras</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hameed</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Beta-human chorionic gonadotropin production associated with phyllodes tumor of the breast: an unusual paraneoplastic phenomenon.</article-title>
            <source>Breast J</source>
            <year>2009</year>
            <season>Sep-Oct</season>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>527</fpage>
            <page-range>527-30</page-range>
            <pub-id pub-id-type="pmid">19624411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kricka</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Human anti-animal antibody interferences in immunological assays.</article-title>
            <source>Clin Chem</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>45</volume>
            <issue>7</issue>
            <fpage>942</fpage>
            <page-range>942-56</page-range>
            <pub-id pub-id-type="pmid">10388468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Check</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Nowroozi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chase</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lauer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elkins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>False-positive human chorionic gonadotropin levels caused by a heterophile antibody with the immunoradiometric assay.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>1988</year>
            <month>Jan</month>
            <volume>158</volume>
            <issue>1</issue>
            <fpage>99</fpage>
            <page-range>99-100</page-range>
            <pub-id pub-id-type="pmid">2447778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knight</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bingemann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cunningham-Rundles</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Frequent false positive beta human chorionic gonadotropin tests in immunoglobulin A deficiency.</article-title>
            <source>Clin Exp Immunol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>141</volume>
            <issue>2</issue>
            <fpage>333</fpage>
            <page-range>333-7</page-range>
            <pub-id pub-id-type="pmid">15996198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fahy</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Gouzd</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Atallah</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy tests with end-stage renal disease.</article-title>
            <source>J Clin Anesth</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>609</fpage>
            <page-range>609-13</page-range>
            <pub-id pub-id-type="pmid">19100935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delbeke</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Van Eenoo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Detection of human chorionic gonadotrophin misuse in sports.</article-title>
            <source>Int J Sports Med</source>
            <year>1998</year>
            <month>May</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>287</fpage>
            <page-range>287-90</page-range>
            <pub-id pub-id-type="pmid">9657371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffey</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Trent</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Bavolek</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Keeperman</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poirier</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>"Hook-like effect" causes false-negative point-of-care urine pregnancy testing in emergency patients.</article-title>
            <source>J Emerg Med</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>155</fpage>
            <page-range>155-60</page-range>
            <pub-id pub-id-type="pmid">21835572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chard</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy tests: a review.</article-title>
            <source>Hum Reprod</source>
            <year>1992</year>
            <month>May</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>701</fpage>
            <page-range>701-10</page-range>
            <pub-id pub-id-type="pmid">1639991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cervinski</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lockwood</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Odem</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Stenman</surname>
                <given-names>UH</given-names>
              </name>
              <name>
                <surname>Alfthan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grenache</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Gronowski</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Qualitative point-of-care and over-the-counter urine hCG devices differentially detect the hCG variants of early pregnancy.</article-title>
            <source>Clin Chim Acta</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>406</volume>
            <issue>1-2</issue>
            <fpage>81</fpage>
            <page-range>81-5</page-range>
            <pub-id pub-id-type="pmid">19477170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Byrn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Human chorionic gonadotropin testing for early pregnancy viability and complications.</article-title>
            <source>Clin Lab Med</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>257</fpage>
            <page-range>257-64, vii</page-range>
            <pub-id pub-id-type="pmid">12848444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butts</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cary</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takacs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sammel</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Predicting the decline in human chorionic gonadotropin in a resolving pregnancy of unknown location.</article-title>
            <source>Obstet Gynecol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>122</volume>
            <issue>2 Pt 1</issue>
            <fpage>337</fpage>
            <page-range>337-343</page-range>
            <pub-id pub-id-type="pmid">23969803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menczer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Modan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serr</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Prospective follow-up of patients with hydatidiform mole.</article-title>
            <source>Obstet Gynecol</source>
            <year>1980</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>346</fpage>
            <page-range>346-9</page-range>
            <pub-id pub-id-type="pmid">7360433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23019.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cole</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Phantom hCG and phantom choriocarcinoma.</article-title>
            <source>Gynecol Oncol</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>71</volume>
            <issue>2</issue>
            <fpage>325</fpage>
            <page-range>325-9</page-range>
            <pub-id pub-id-type="pmid">9826481</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
